Search

Your search keyword '"Huanling Zhu"' showing total 19 results

Search Constraints

Start Over You searched for: Author "Huanling Zhu" Remove constraint Author: "Huanling Zhu" Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
19 results on '"Huanling Zhu"'

Search Results

1. Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia

2. Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors

3. Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN

4. Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia

5. Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes

6. S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS

8. PB1968: IMPACTS ON OUTCOMES AND A PREDICTIVE MODEL OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA RECEIVING INITIAL NILOTINIB-THERAPY

10. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

11. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

12. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

14. Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services

15. Antiproliferative and Apoptosis Triggering Potential of Paclitaxel-Based Targeted-Lipid Nanoparticles with Enhanced Cellular Internalization by Transferrin Receptors—a Study in Leukemia Cells

16. Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia

17. Activation of the hedgehog pathway in chronic myelogeneous leukemia patients.

18. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.

19. Immunomodulatory effects of mesenchymal stem cells involved in favoring type 2 T cell subsets.

Catalog

Books, media, physical & digital resources